Published in J Exp Med on December 03, 2001
Coexpression analysis of human genes across many microarray data sets. Genome Res (2004) 9.38
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A (2003) 3.45
Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet (2012) 3.08
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.60
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A (2008) 2.41
Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest (2005) 2.40
Variation in gene expression patterns in human gastric cancers. Mol Biol Cell (2003) 2.39
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A (2011) 2.12
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood (2007) 2.00
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood (2009) 1.89
ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol (2010) 1.88
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A (2003) 1.84
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med (2008) 1.82
Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood (2010) 1.79
B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol (2013) 1.72
How I treat CLL up front. Blood (2009) 1.71
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood (2007) 1.69
Retracted The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest (2004) 1.68
Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res (2003) 1.68
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood (2008) 1.67
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood (2008) 1.67
Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest (2012) 1.64
Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol (2009) 1.64
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood (2012) 1.61
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med (2015) 1.57
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.57
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. Blood (2015) 1.55
The emerging role of CXCL10 in cancer (Review). Oncol Lett (2011) 1.54
Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res (2013) 1.51
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood (2006) 1.50
Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology (2005) 1.41
Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med (2012) 1.40
Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. PLoS One (2015) 1.37
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med (2009) 1.35
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification. Blood (2006) 1.29
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am (2013) 1.22
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One (2011) 1.21
High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood (2009) 1.20
Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of Cell Proliferation, Cancer Malignancy, and Barriergenesis. Genes Cancer (2010) 1.20
Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One (2009) 1.18
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood (2011) 1.18
Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood (2012) 1.16
Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. J Biol Chem (2008) 1.15
Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene (2011) 1.13
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One (2011) 1.12
Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. Am J Pathol (2002) 1.12
Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology (2012) 1.10
A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica (2009) 1.08
WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3. Br J Pharmacol (2014) 1.07
TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. J Immunol (2011) 1.07
Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica (2011) 1.07
Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One (2010) 1.07
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol (2010) 1.07
The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res (2014) 1.04
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood (2009) 1.03
Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood (2007) 1.01
The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol (2013) 1.01
Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A (2013) 1.00
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 1.00
Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells. J Immunol (2002) 0.98
An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol (2004) 0.98
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res (2009) 0.98
Targeting malignant B cells with an immunotoxin against ROR1. MAbs (2012) 0.98
Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood (2009) 0.98
Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica (2009) 0.97
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn (2008) 0.97
Pivotal Role of AKAP12 in the Regulation of Cellular Adhesion Dynamics: Control of Cytoskeletal Architecture, Cell Migration, and Mitogenic Signaling. J Signal Transduct (2012) 0.96
Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther (2013) 0.96
Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg Med Chem Lett (2010) 0.96
Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J Exp Med (2008) 0.95
Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood (2015) 0.95
Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica (2009) 0.95
HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest (2005) 0.95
ZAP70: a master regulator of adaptive immunity. Semin Immunopathol (2010) 0.93
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood (2007) 0.93
LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Haematologica (2011) 0.93
Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget (2012) 0.93
CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progression. PLoS One (2013) 0.93
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. J Mol Diagn (2007) 0.92
Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene (2012) 0.92
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica (2009) 0.91
How will B-cell-receptor-targeted therapies change future CLL therapy? Blood (2014) 0.90
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood (2010) 0.89
Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One (2012) 0.89
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Wnt signaling and cancer. Genes Dev (2000) 18.53
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. Genomics (1996) 11.71
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 11.50
Intraclonal generation of antibody mutants in germinal centres. Nature (1991) 7.39
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest (1998) 3.96
Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity (2000) 3.19
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53
Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol (1994) 2.52
Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today (2000) 2.43
p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol (2000) 2.42
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Somatic hypermutation in normal and transformed human B cells. Immunol Rev (1998) 2.22
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med (1989) 2.16
Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol (1997) 1.91
The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev (1998) 1.81
Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol (1997) 1.61
Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood (1990) 1.58
Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun (1988) 1.49
Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J Invest Dermatol (1999) 1.37
Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol (2001) 1.25
Identification of a Frizzled-like cysteine rich domain in the extracellular region of developmental receptor tyrosine kinases. Protein Sci (1998) 1.05
AICL: a new activation-induced antigen encoded by the human NK gene complex. Immunogenetics (1997) 1.04
CD5-positive B cells in healthy elderly humans are a polyclonal B cell population. Eur J Immunol (2000) 1.00
Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. Blood (1996) 0.91
Leukemic cells from progressive B-CLL respond strongly to growth stimulation in vitro. Leukemia (1994) 0.89
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Molecular portraits of human breast tumours. Nature (2000) 94.14
Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 88.48
Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics (1989) 79.44
Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet (1980) 75.25
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol Biol Cell (1998) 62.20
Exploring the metabolic and genetic control of gene expression on a genomic scale. Science (1997) 60.15
The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res (2004) 54.37
The transcriptional program of sporulation in budding yeast. Science (1998) 37.23
Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell (2000) 36.09
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Comparative genomics of the eukaryotes. Science (2000) 26.62
Two differentially regulated mRNAs with different 5' ends encode secreted with intracellular forms of yeast invertase. Cell (1982) 25.10
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A (1996) 24.18
A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res (1996) 23.16
Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. Nature (2001) 21.55
Genetic and physical maps of Saccharomyces cerevisiae. Nature (1997) 21.48
Missing value estimation methods for DNA microarrays. Bioinformatics (2001) 20.84
Genetic engineering in vivo using translocatable drug-resistance elements. New methods in bacterial genetics. J Mol Biol (1977) 20.29
SGD: Saccharomyces Genome Database. Nucleic Acids Res (1998) 20.26
A Saccharomyces cerevisiae genomic plasmid bank based on a centromere-containing shuttle vector. Gene (1987) 19.68
Sterile host yeasts (SHY): a eukaryotic system of biological containment for recombinant DNA experiments. Gene (1979) 19.39
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Exploring the new world of the genome with DNA microarrays. Nat Genet (1999) 19.05
Integrating functional genomic information into the Saccharomyces genome database. Nucleic Acids Res (2000) 18.52
Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A (2000) 18.42
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
A common language for physical mapping of the human genome. Science (1989) 17.36
Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet (1996) 15.73
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet (1999) 14.96
Flexible regression models with cubic splines. Stat Med (1989) 14.45
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Using the Saccharomyces Genome Database (SGD) for analysis of protein similarities and structure. Nucleic Acids Res (1999) 13.65
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
Promoter-specific binding of Rap1 revealed by genome-wide maps of protein-DNA association. Nat Genet (2001) 13.05
DNA arrays for analysis of gene expression. Methods Enzymol (1999) 12.50
Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. Science (1987) 12.20
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Mutagenesis by insertion of a drug-resistance element carrying an inverted repetition. J Mol Biol (1975) 11.14
Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell (2000) 10.90
Correct integration of retroviral DNA in vitro. Cell (1987) 10.73
Structure and function of the yeast URA3 gene: expression in Escherichia coli. Gene (1984) 10.07
Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med (1998) 9.72
Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms. Proc Natl Acad Sci U S A (1986) 9.51
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev (1989) 8.80
A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature (1986) 8.64
Signaling of cell fate decisions by CLAVATA3 in Arabidopsis shoot meristems. Science (1999) 8.61
Data management and analysis for gene expression arrays. Nat Genet (1998) 8.60
Phenotypic analysis of temperature-sensitive yeast actin mutants. Cell (1985) 8.53
Mapping complex genetic traits in humans: new methods using a complete RFLP linkage map. Cold Spring Harb Symp Quant Biol (1986) 8.22
Gaussian models for genetic linkage analysis using complete high-resolution maps of identity by descent. Am J Hum Genet (1993) 8.05
The Stanford Microarray Database. Nucleic Acids Res (2001) 7.77
The CONSTANS gene of Arabidopsis promotes flowering and encodes a protein showing similarities to zinc finger transcription factors. Cell (1995) 7.76
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Integration of murine leukemia virus DNA depends on mitosis. EMBO J (1993) 7.62
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
The yeast GTP-binding YPT1 protein and a mammalian counterpart are associated with the secretion machinery. Cell (1988) 7.39
Plasmid construction by homologous recombination in yeast. Gene (1987) 7.26
Diverse effects of beta-tubulin mutations on microtubule formation and function. J Cell Biol (1988) 6.88
Lethal disruption of the yeast actin gene by integrative DNA transformation. Science (1982) 6.88
Evidence for transcriptional regulation of orotidine-5'-phosphate decarboxylase in yeast by hybridization of mRNA to the yeast structural gene cloned in Escherichia coli. Proc Natl Acad Sci U S A (1979) 6.81
Properties of the translocatable tetracycline-resistance element Tn10 in Escherichia coli and bacteriophage lambda. Genetics (1978) 6.73
Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med (2001) 6.66
Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science (1997) 6.58